Reduction in Total Cardiovascular Events with Ezetimibe/Simvastatin Post-Acute Coronary Syndrome the IMPROVE-IT Trial

Journal of the American College of Cardiology

Volumn 67, Issue 4, 2016, Pages 353-361

  Murphy, Sabina A ^a   Cannon, Christopher P ^a   Blazing, Michael A ^b   Giugliano, Robert P ^a   White, Jennifer A ^b   Lokhnygina, Yuliya ^b   Reist, Craig ^b   Im, Kyungah ^a   Bohula, Erin A ^a   Isaza, Daniel ^c   Lopez Sendon, Jose ^d   Dellborg, Mikael ^e   Kher, Uma ^f   Tershakovec, Andrew M ^f   Braunwald, Eugene ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c FUNDACIÓN CARDIOINFANTIL INSTITUTO DE CARDIOLOGÍA   (Colombia)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

ezetimibe; low density lipoprotein cholesterol; simvastatin; total events

Indexed keywords

EZETIMIBE; PLACEBO; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSTABLE ANGINA PECTORIS; BLOOD; COMBINATION DRUG THERAPY; DOSE RESPONSE; DRUG EFFECTS; INCIDENCE; MIDDLE AGED; MYOCARDIAL INFARCTION; SURVIVAL RATE; TIME FACTOR; TREATMENT OUTCOME; TRENDS; UNITED STATES;

ACUTE CORONARY SYNDROME; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EZETIMIBE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; SIMVASTATIN; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84959370789     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.10.077     Document Type: Article

References (25)

1. S.A. Murphy, C.P. Cannon, S.D. Wiviott, C.H. McCabe, and E. Braunwald Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial J Am Coll Cardiol 54 2009 2358 2362
2. M.J. Tikkanen, M. Szarek, R. Fayyad, and et al. Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial J Am Coll Cardiol 54 2009 2353 2357
3. C.P. Cannon, M.A. Blazing, R.P. Giugliano, and et al. Ezetimibe added to statin therapy after acute coronary syndromes N Engl J Med 372 2015 2387 2397
4. C.P. Cannon, R.P. Giugliano, M.A. Blazing, and et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes Am Heart J 156 2008 826 832
5. M.A. Blazing, R.P. Giugliano, C.P. Cannon, and et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population Am Heart J 168 2014 205 212.e1
6. R.M. Califf, Y. Lokhnygina, C.P. Cannon, and et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design Am Heart J 159 2010 705 709
7. L.J. Wei, D.Y. Lin, and L. Weissfeld Regression analysis of multivariate incomplete failure time data by modeling marginal distributions J Amer Statis Assoc 84 1989 1068 1073
8. R.L. Prentice, B.J. Williams, and A.V. Peterson On the regression analysis of multivariate failure time data Biometrika 68 1981 373 379
9. C. Baigent, A. Keech, P.M. Kearney, and et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
10. C. Baigent, L. Blackwell, J. Emberson, and et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
11. C.P. Cannon, E. Braunwald, C.H. McCabe, and et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
12. J.A. de Lemos, M.A. Blazing, S.D. Wiviott, and et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial JAMA 292 2004 1307 1316
13. J.C. LaRosa, S.M. Grundy, D.D. Waters, and et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
14. T.R. Pedersen, O. Faergeman, J.J. Kastelein, and et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 294 2005 2437 2445
15. C.P. Cannon, B.A. Steinberg, S.A. Murphy, and et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy J Am Coll Cardiol 48 2006 438 445
16. J.C. LaRosa, P.C. Deedwania, J. Shepherd, and et al. Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial) Am J Cardiol 105 2010 283 287
17. W.E. Boden, J.L. Probstfield, T. Anderson, and et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
18. M.J. Landray, R. Haynes, J.C. Hopewell, and et al. Effects of extended-release niacin with laropiprant in high-risk patients N Engl J Med 371 2014 203 212
19. P.J. Barter, M. Caulfield, M. Eriksson, and et al. Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
20. G.G. Schwartz, A.G. Olsson, M. Abt, and et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome N Engl J Med 367 2012 2089 2099
21. J.A. Spertus, M.J. Radford, N.R. Every, and et al. Challenges and opportunities in quantifying the quality of care for acute myocardial infarction: summary from the Acute Myocardial Infarction Working Group of the American Heart Association/American College of Cardiology First Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Circulation 107 2003 1681 1691
22. M. Gold, J. Siegel, L. Russel, and M. Weinstein Cost-Effectiveness in Health and Medicine 1996 Oxford University Press New York, NY
23. S.J. Pocock, C.A. Ariti, T.J. Collier, and D. Wang The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities Eur Heart J 33 2012 176 182
24. J.A. Bakal, C.M. Westerhout, W.J. Cantor, and et al. Evaluation of early percutaneous coronary intervention vs. standard therapy after fibrinolysis for ST-segment elevation myocardial infarction: contribution of weighting the composite endpoint Eur Heart J 34 2013 903 908
25. J.A. Bakal, M.T. Roe, E.M. Ohman, and et al. Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial Eur Heart J 36 2015 385 392a